Table 2.
Subjective assessment of presence of scar in the human subjects (Groups 1 and 2) and in the animals
| LV scara | Papillary muscle scara | |||||
|---|---|---|---|---|---|---|
| GB-LGE | BB-LGE | Conventional LGEb | GB-LGE | BB-LGE | Conventional LGEb | |
| Reader 1 | ||||||
| Group 1 | 9/18/0 | 9/17/1 | 6/19/2 | 14/13/0 | 12/15/0 | 10/17/0 |
| Group 2 | 8/10/0 | n.a. | 6/12/0 | 3/15/0 | n.a. | 3/15/0 |
| Animals | 5/0/0 | 5/0/0 | 5/0/0 | 0/5/0 | 0/5/0 | 0/5/0 |
| Reader 2 | ||||||
| Group 1 | 9/18/0 | 9/17/1 | 6/17/4 | 17/10/0 | 13/13/1 | 13/14/0 |
| Group 2 | 8/10/0 | n.a. | 7/11/0 | 3/15/0 | n.a. | 3/15/0 |
| Animals | 5/0/0 | 5/0/0 | 5/0/0 | 0/5/0 | 0/5/0 | 0/5/0 |
aData represent the number of cases scored as yes/no/uncertain regarding the presence of scar. Lack of BB-LGE data in group 2 is represented by ‘n.a.’ (i.e, not-available). GB gray blood, BB black blood, LGE late gadolinium enhancement
bLGE (humans) or phase-sensitive LGE (animals)